HCAR1: The Lactate Receptor’s Role in Metabolism and Disease

HCAR1, also known as GPR81, is a receptor on cell surfaces that detects lactate and translates that signal into changes in metabolism, fat storage, brain activity, and immune responses. First identified in fat tissue as a brake on fat breakdown, HCAR1 has since turned up in the brain, the gut lining, tumors, and muscle fibers, each time doing something slightly different with the same basic signal. The receptor sits at a crossroads where exercise physiology, cancer biology, and metabolic disease all converge, which is why it has drawn so much research attention over the past decade and a half.

How HCAR1 Was Discovered and What It Does at the Molecular Level

For years, lactate was considered little more than a waste product of hard-working muscles. That view began to shift in 2008, when researchers showed that an orphan receptor called GPR81, sitting primarily on fat cells, could bind lactate and suppress the breakdown of stored fat. That study used both pharmacological tools and genetically modified mice to demonstrate that GPR81 functions as a bona fide lactate receptor with an anti-lipolytic effect.¹ The receptor was later renamed HCAR1 (hydroxycarboxylic acid receptor 1) to reflect its place in a small family of related receptors that sense organic acids.

When lactate binds HCAR1, the receptor activates an inhibitory G protein (Gi), which lowers levels of cyclic AMP inside the cell.² Since cyclic AMP drives many energy-mobilizing processes, dialing it down essentially tells the cell to stop releasing stored fuel. Recent signaling-profiling work has added nuance: HCAR1 activates all members of the Gi/o subfamily, and, unexpectedly, also recruits Gs (the stimulatory G protein) at higher agonist concentrations, while showing little to no recruitment of beta-arrestin.³ The absence of beta-arrestin recruitment is pharmacologically interesting because it means HCAR1 may resist the desensitization that many other receptors undergo when repeatedly stimulated. In other words, the signal stays on as long as lactate is present.

Fat Metabolism and Insulin Sensitivity

The first and still best-understood role of HCAR1 is in fat tissue. When lactate rises in the blood, whether from exercise, eating, or metabolic stress, it activates HCAR1 on fat cells and suppresses lipolysis, the process by which stored fat is broken down into free fatty acids and released into the bloodstream. This was confirmed in knockout mice: when researchers infused lactate into mice lacking HCAR1, fatty acid levels still dropped, but the drop was smaller than in normal mice, indicating that lactate suppresses lipolysis partly through HCAR1 and partly through other mechanisms.⁴

The receptor also appears in brown fat, the metabolically active tissue that burns calories to generate heat. In diet-induced obese mice, overexpressing HCAR1 specifically in brown fat restored glucose tolerance and insulin sensitivity. Those mice showed reduced activation of hormone-sensitive lipase (the enzyme that breaks down stored fat) and increased expression of genes involved in building new fat stores within the brown fat itself. The net result was weight loss and better blood sugar control.⁵ These findings suggest HCAR1 may be especially relevant in conditions where insulin signaling is already impaired. Modeling work in the same Cell Metabolism study found that HCAR1 becomes more important for keeping lactate levels stable when insulin is insufficient, as in diabetes, hinting that the receptor could be a compensatory player during metabolic dysfunction.⁴

The Brain Side of the Story

HCAR1 is not limited to fat. It is expressed in the cerebral cortex, the hippocampus, and along the blood-brain barrier, where it responds to the physiological concentrations of lactate that circulate during normal brain activity and exercise.⁶ The brain uses lactate as a fuel, especially when neurons are highly active, so having a receptor that senses lactate levels and adjusts neuronal behavior makes physiological sense.

In cultured cortical neurons, activating HCAR1 decreases spontaneous calcium spiking by about 40%, reduces the frequency of miniature excitatory signals, and lowers overall firing rates. These effects vanish in neurons taken from HCAR1 knockout mice, confirming they are receptor-dependent. Interestingly, neurons lacking HCAR1 show higher baseline activity than normal neurons, which implies the receptor normally keeps excitatory tone in check.⁷ The receptor achieves this through both its Gi-alpha and Gi-beta-gamma subunits, and it interacts with other inhibitory receptors for adenosine, GABA, and noradrenaline, adding layers of modulation rather than acting as a simple on/off switch.

A separate and fascinating story is emerging in the hypothalamus, the brain region that governs appetite and energy balance. A recent study found that HCAR1 is highly expressed in hypothalamic astrocytes, the support cells that nourish neurons. When specialized cells called tanycytes detect glucose in the cerebrospinal fluid, they produce lactate, which then activates HCAR1 on nearby astrocytes. The astrocytes respond by releasing glutamate, which in turn excites POMC neurons, a neuronal population that suppresses appetite. Silencing HCAR1 in astrocytes abolished this entire cascade.⁸ This glial relay suggests HCAR1 helps the brain monitor energy availability and adjust feeding behavior accordingly, a function that could eventually be relevant to understanding obesity and metabolic syndrome.

Exercise, Brain Blood Vessels, and VEGF

One of the more striking findings about HCAR1 connects exercise to brain blood vessel growth. In mice subjected to seven weeks of high-intensity interval training, brain levels of VEGF-A (a key growth factor for new blood vessels) increased, and the density of brain capillaries rose along with it. The same effect occurred when researchers simply injected lactate under the skin to mimic the blood lactate increase of exercise. Critically, neither exercise nor lactate injection produced these vascular changes in HCAR1 knockout mice, establishing the receptor as a required link in the chain.⁹ The receptor was found concentrated in fibroblast-like cells along the brain’s surface blood vessels and in pericyte-like cells lining intracerebral microvessels, precisely where you would expect a regulator of blood vessel growth to sit.

Developmental work in younger animals has added to this picture. Lactate stimulation of neurons increases growth factors including VEGF, angiopoietins, and PDGF while reducing an anti-angiogenic signal, together accelerating blood vessel formation.¹⁰ The implication is that HCAR1 contributes to keeping the brain adequately supplied with blood, both during development and in adult life when exercise pushes lactate levels up. For people interested in the cognitive benefits of exercise, HCAR1-driven angiogenesis is one plausible biological pathway.

What About Neuroprotection After a Stroke?

Lactate itself has shown protective effects in models of brain ischemia (stroke), and researchers naturally wondered whether HCAR1 was responsible. The answer, at least from one mouse study, is probably not. Administering HCAR1 agonists at the time of reperfusion did not reproduce the protective effects of lactate itself, leading the researchers to conclude that lactate’s benefits after ischemia come from its role as an energy substrate rather than from signaling through HCAR1.¹¹ This is a useful reminder that lactate does many things in the body, and not all of them run through HCAR1.

Cancer and Immune Evasion

Tumors are voracious consumers of glucose, and they pump out lactate as a byproduct, creating an acidic, lactate-rich microenvironment. HCAR1 is highly expressed in several cancer types, and its presence is not passive. In breast cancer cells, knocking out HCAR1 reduced both proliferation and migration, suggesting the receptor actively promotes tumor growth and spread.¹² Separate work has shown that stimulating HCAR1 affects a cell’s DNA repair capacity, potentially giving tumor cells an additional survival advantage.¹³

Perhaps more concerning is HCAR1’s role in helping tumors evade the immune system. In colorectal cancer models, activating HCAR1 on tumor cells induced them to produce chemokines CCL2 and CCL7, which recruit a specific type of immunosuppressive immune cell (polymorphonuclear myeloid-derived suppressor cells, or PMN-MDSCs) into the tumor. When HCAR1 was deleted in these mice, fewer suppressor cells arrived, CD8+ T cells became more active, and tumor burden shrank.¹⁴ This mechanism effectively turns a tumor’s metabolic waste into a shield against immune attack. Lactate-driven HCAR1 signaling appears to simultaneously recruit suppressive immune cells and inhibit T-cell function, creating a doubly immunosuppressive environment.¹⁵

The oncology angle makes HCAR1 a potential drug target. But there is an obvious tension: the same receptor that helps tumors evade immune surveillance also suppresses lipolysis, promotes brain blood vessel growth, and calms overexcited neurons. Any drug that blocks HCAR1 system-wide to fight cancer would presumably disrupt these other functions. That challenge is pushing researchers toward more targeted approaches.

The Gut Barrier Connection

A newer frontier for HCAR1 research is the intestine. Gut bacteria produce both L-lactate and D-lactate at millimolar concentrations, and it turns out HCAR1 sits on the apical (lumen-facing) surface of human colonic epithelial cells. In a cell model, both forms of lactate activated Gi signaling through HCAR1, though L-lactate triggered a stronger and faster response. Applying lactate to the apical side, but not the basal side, strengthened tight junctions between cells and reduced permeability, consistent with where the receptor actually sits.¹⁶

If this finding holds up in vivo, it would add an interesting dimension to the conversation about gut health. Probiotic bacteria, particularly lactic acid bacteria, are known for producing lactate. A functional HCAR1 on the gut lining could be one mechanism by which those bacteria actually strengthen the intestinal barrier, moving the discussion from vague “gut health” claims to a specific molecular pathway. The research is early-stage, using cell culture rather than animal or human models, but the observation that HCAR1 is polarized to the gut’s inner surface and responds to microbially produced lactate is a logical fit.

HCAR1 in Skeletal Muscle

Given that exercising muscle is the body’s biggest lactate producer, you might expect HCAR1 to play a major signaling role there. The receptor is indeed present in human skeletal muscle, but its distribution is uneven. HCAR1 protein is predominantly found in type II (fast-twitch) muscle fibers, the ones that generate the most lactate during intense exercise. This localization led researchers to propose that lactate acts as an autocrine signal in muscle, meaning the same fibers that produce it also sense it.¹⁷ However, the same study found that lactate did not appear to regulate CREB signaling during exercise, leaving the precise downstream consequences in muscle unclear. The receptor is there, the ligand is abundant, but what the conversation between them accomplishes in muscle remains an open question.

How HCAR1 Compares to Its Receptor Relatives

HCAR1 belongs to a small family alongside HCAR2 (which senses the ketone body beta-hydroxybutyrate and is the target of the anti-inflammatory drug niacin) and HCAR3 (which responds to 3-hydroxyoctanoic acid). Despite the family name, HCAR1 is the odd one out. HCAR2 and HCAR3 share about 96% of their amino acid sequence, differing by only 15 residues across most of their structure. By contrast, HCAR1 shares only about 48–49% sequence identity with either sibling.¹⁸

Structural studies have shown that HCAR1 achieves this selectivity partly through a more compact binding pocket, stabilized by three disulfide bonds that are unique to HCAR1 and not found in HCAR2.¹⁹ The tighter pocket explains why HCAR1 prefers small hydroxy acids like lactate while HCAR2 accommodates the bulkier beta-hydroxybutyrate. For drug design, this structural divergence is useful: it means compounds can potentially be made selective for one family member without triggering the others, which matters because HCAR2 activation has its own set of physiological effects (including the infamous niacin flush).

Drug Discovery and the Road Ahead

Most studies on HCAR1 have relied on lactate itself or on synthetic agonists like 3,5-dihydroxybenzoic acid and 3-chloro-5-hydroxybenzoic acid, which are useful research tools but not realistic drug candidates. The pharmacological toolkit has recently expanded. Signaling profiling has identified compounds like AZ7136 as a relatively potent HCAR1 agonist and GPR81 agonist 1 as an ago-positive allosteric modulator, a compound that both activates the receptor on its own and boosts the effect of lactate when it binds.³ Allosteric modulators are prized in drug design because they tend to be more selective and produce fewer side effects than compounds that compete directly with the natural ligand.

On the antagonist side, where the cancer field is most interested, machine-learning approaches have been deployed to sift through thousands of compounds and predict which ones might block HCAR1. One recent effort trained a classification model on known agonists and antagonists from structurally related receptors and screened over 3,300 compounds, flagging several with antagonist-like features, including two FDA-approved drugs (Ketanserin and Cefuroxime) that could theoretically be repurposed.²⁰ These are computational predictions, not clinical results, but they illustrate how the field is attempting to fast-track antagonist development. The challenge remains that blocking HCAR1 in tumors while preserving its beneficial roles in fat tissue, the brain, and the gut will likely require tissue-targeted delivery strategies rather than a systemically available pill.

Cryo-EM structures of HCAR1 bound to its G protein and various ligands are now available, revealing specific residues in the binding pocket whose mutation disrupts receptor activation. For instance, mutations to hydrophobic residues within the orthosteric binding pocket, particularly at positions in extracellular loop 2 and the upper transmembrane region, noticeably reduce agonist activity.²¹ These structural details give medicinal chemists something to design around, a three-dimensional map of what the perfect HCAR1-binding molecule should look like. Ten years ago, nobody even knew what HCAR1 looked like at atomic resolution. Now there are multiple high-resolution structures, a growing library of agonists and modulators, machine-learning pipelines for antagonist discovery, and clear disease-area rationale in both metabolic disease and oncology. The receptor has gone from an obscure orphan to a bona fide therapeutic target in a remarkably short span.